Agent Orange exposure was not linked with poor prognostic factors or shortened overall survival in patients with chronic lymphocytic leukemia (CLL), according to a retrospective study involving >2,000 individuals. Participants were Vietnam veterans with CLL. Investigators looked at the impact of Agent Orange exposure on CLL prognosis, treatment, and survival. Among the results:
- Prognostic factors were not different based on exposure.
- Exposed veterans were diagnosed at an average of ~63 years of age, vs ~70 in those who were not exposed.
- Median overall survival was not reached in the exposed group, vs 91 months in those who were not exposed.
- Prolonged survival in the exposed group tended to occur in patients between 60 and 69 years of age, as well as those with 11q deletion.
- 4 in every 10 exposed patients were treated with fludarabine, chlorambucil, and rituximab, vs 2 in every 10 of those who were not exposed.
- Treatment with bendamustine plus rituximab occurred in 25% and 18%, respectively.
Mescher C, Gilbertson D, Randall N, et al. The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: A National Veteran Affairs Tumor Registry Study. [Published online ahead of print September 14, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1375109.